Anzeige
Mehr »
Montag, 19.01.2026 - Börsentäglich über 12.000 News
Goldaktie des Tages: Weiteres Upside-Potential enorm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJVC | ISIN: KYG4403H1002 | Ticker-Symbol: 6XY
Tradegate
19.01.26 | 08:39
1,540 Euro
-2,53 % -0,040
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
HBM HOLDINGS LTD Chart 1 Jahr
5-Tage-Chart
HBM HOLDINGS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,4601,59013:00
1,4701,54012:58

Aktuelle News zur HBM HOLDINGS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02:29Harbour BioMed Exercises Warrant To Acquire Stake In Spruce Biosciences1
01:02Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration49CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to...
► Artikel lesen
HBM HOLDINGS Aktie jetzt für 0€ handeln
01:00HBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - EXERCISE OF WARRANT UNDER LICENSE AND COLLABORATION AGREEMENT WITH SPRUCE BIOSCIENCES INC.1
02.01.Harbour BioMed, Lannacheng Partner to Advance Next-Gen RDCs2
02.01.HBM HOLDINGS-B (02142): (REVISED) NEXT DAY DISCLOSURE RETURN1
01.01.HBM HOLDINGS-B (02142): GRANT OF SHARE OPTIONS1
30.12.25HBM HOLDINGS-B (02142): NEXT DAY DISCLOSURE RETURN4
29.12.25Harbour BioMed Collaborates With Lannacheng To Advance Next-Generation Radionuclide Drug Conjugates2
29.12.25Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates80CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed...
► Artikel lesen
17.12.25Harbour BioMed, BMS Partner to Advance Next-Gen Multi-Specific Antibodies9
17.12.25Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B6
17.12.25Harbour BioMed and BMS sign multi-specific antibody collab3
17.12.25Harbour BioMed, Bristol Myers More Than $1.1 Bln Deal For Next-Gen Multi-Specific Antibodies497NEW YORK CITY (dpa-AFX) - Harbour BioMed (2142.HK) announced that it has entered into a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb. The partnership...
► Artikel lesen
17.12.25Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies135SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, Dec. 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed...
► Artikel lesen
17.12.25HBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - ENTERING INTO GLOBAL STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH BRISTOL MYERS SQUIBB1
15.12.25HBM HOLDINGS-B (02142): NEXT DAY DISCLOSURE RETURN-
05.12.25HBM HOLDINGS-B (02142): NEXT DAY DISCLOSURE RETURN1
28.11.25HBM HOLDINGS-B (02142): NEXT DAY DISCLOSURE RETURN-
24.11.25HBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - ADVANCEMENT OF GLOBAL COLLABORATION WITH ASTRAZENECA2
19.11.25HBM HOLDINGS-B (02142): VOLUNTARY ANNOUNCEMENT - ENTERING INTO NON-EXCLUSIVE LICENSE AGREEMENT WITH PFIZER1
Weiter >>
56 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1